| Phase 19 trials |
|
Phase 1
|
NCT05150626 |
May → Jun 2022 |
— |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05146869 |
Dec 2021 → Mar 2022 |
type 2 diabetes mellitus |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05072028 |
Nov 2021 |
— |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05045313 |
Oct → Dec 2021 |
— |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04859439 |
Jun → Nov 2021 |
impaired renal function disease |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04859426 |
Jun 2021 → May 2022 |
— |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04859452 |
May → Jul 2021 |
— |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02163278 |
Jun 2014 → Jan 2015 |
type 2 diabetes mellitus |
National Health Research Institutes, Taiwan |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT01650324 |
Jul → Dec 2012 |
type 2 diabetes mellitus |
National Health Research Institutes, Taiwan |
Completed
|
No outcome recorded
|
| Phase 21 trial |
|
Phase 2
|
NCT04124484 |
Oct 2017 → Feb 2019 |
type 2 diabetes mellitus |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
Completed
|
No outcome recorded
|
| Phase 33 trials |
|
Phase 3
|
NCT07026968 |
Jun 2025 → Oct 2026 expected |
type 2 diabetes mellitus |
CSPC Ouyi Pharmaceutical Co., Ltd. |
Active not recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT04218734 |
Jan 2020 → Jun 2021 |
type 2 diabetes mellitus |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT04161430 |
Jan 2020 → Jun 2022 |
type 2 diabetes mellitus |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
Completed
|
No outcome recorded
|